[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.150.215. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 4, 1994

Alzheimer's Disease, Apolipoprotein E4, and Gender

Author Affiliations

Oregon Health Sciences University Portland; University of Washington Seattle

JAMA. 1994;271(17):1316-1317. doi:10.1001/jama.1994.03510410028015
Abstract

To the Editor.  —Researchers at Duke University have shown that apolipoprotein E4 (apo E) gene dosage correlates with increased risk of Alzheimer's disease (AD).1 Their study included members of 42 families with late-onset AD (age at onset, >60 years) with known apo E genotype and used Kaplan-Meier survival analysis to estimate the age-of-onset curves for subjects with zero, one, and two E4 alleles. The resulting curves revealed a significant dosage effect, where each additional E4 allele shifted the onset to an earlier age.We have performed a similar study, which included members of 52 families with late-onset AD (age at onset, >60 years) with known apo E genotype and used Kaplan-Meier survival analysis to estimate the age-of-onset curves for subjects with zero, one, and two E4 alleles. Our study included 252 individuals with known age and apo E genotype; 38 were younger than 60 years,

First Page Preview View Large
First page PDF preview
First page PDF preview
×